At BLEEDnFIRE Therapeutics, we are pioneering innovative siRNA-based therapies for hemophilia, Von Willebrand disease & other rare bleeding disorders (RBDs) by developing BnF-001. Our mission is to transform patient care and improve quand improve quality of life through targeted & effective novel therapies. BnF-001 works by targeting & reducing the activity of protein S, a factor in the blood that prevents clotting. BnF-001 helps to promote clotting, thereby reducing the risk of bleeding. BnF-001 represents a new class of RNA therapeutics, which are cost-effective, easy to produce, and can safely target pathways that were previously difficult to treat. We own 3 patent families with market rights in US/KR/JP/IL and nationalization phase ongoing in other countries.